Evidence map›Paper›PMID 38182845›Full record

ReviewDermatology and therapy2024

Cutaneous Components Leading to Pruritus, Pain, and Neurosensitivity in Atopic Dermatitis: A Narrative Review.

Sonja Ständer, Thomas Luger, Brian Kim, Ethan Lerner, Martin Metz, Roni Adiri, Juliana M Canosa, Amy Cha, Gil Yosipovitch

Open access · goldAbstract readReview
In one paragraph

Review in Dermatology and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
13.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 25 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 3 countries.

Sonja StänderCenter for Chronic Pruritus, Münster University Hospital, Münster, Germany. Sonja.Staender@ukmuenster.de.ORCID http://orcid.org/0000-0003-3612-7786
Thomas LugerUniversity Hospital Münster, Münster, Germany.
Brian KimCenter for the Study of Itch and Sensory Disorders, Washington University School of Medicine, St. Louis, MO, USA.
Ethan LernerMassachusetts General Hospital, Charlestown, MA, USA.
Martin MetzInstitute of Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Roni AdiriPfizer Pharmaceuticals Israel Ltd, Herzliya Pituach, Israel.
Juliana M CanosaPfizer Brasil Ltda, São Paulo, SP, Brazil.
Amy ChaPfizer Inc, New York, NY, USA.
Gil YosipovitchPfizer Inc, New York, NY, USA.
University Hospital Münster · DE3M (Israel) · ILFraunhofer Institute for Translational Medicine and Pharmacology · DEMassachusetts General Hospital · USPfizer (United States) · USUniversity of Miami · USWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atopic dermatitis (AD) is a chronic, relapsing immunoinflammatory skin condition characterized by sensations such as pruritis, pain, and neuronal hypersensitivity. The mechanisms underlying these sensations are multifactorial and involve complex crosstalk among several cutaneous components. This review explores the role these components play in the pathophysiology of atopic dermatitis. In the skin intercellular spaces, sensory nerves interact with keratinocytes and immune cells via myriad mediators and receptors. These interactions generate action potentials that transmit pruritis and pain signals from the peripheral nervous system to the brain. Keratinocytes, the most abundant cell type in the epidermis, are key effector cells, triggering crosstalk with immune cells and sensory neurons to elicit pruritis, pain, and inflammation. Filaggrin expression by keratinocytes is reduced in atopic dermatitis, causing a weakened skin barrier and elevated skin pH. Fibroblasts are the main cell type in the dermis and, in atopic dermatitis, appear to reduce keratinocyte differentiation, further weakening the skin barrier. Fibroblasts and mast cells promote inflammation while dermal dendritic cells appear to attenuate inflammation. Inflammatory cytokines and chemokines play a major role in AD pathogenesis. Type 2 immune responses typically generate pruritis, and the type 1 and type 3 responses generate pain. Type 2 responses and increased skin pH contribute to barrier dysfunction and promote dysbiosis of the skin microbiome, causing the proliferation of Staphyloccocus aureus. In conclusion, understanding the dynamic interactions between cutaneous components in AD could drive the development of therapies to improve the quality of life for patients with AD.

Indexed as

AlloknesisChronic itchHyperknesisKeratinocyteNeuroimmunologyNeuronal sensitizationSensory biologySkin painSkin physiology

Identifiers

PMID38182845
PMCPMC10828226
OpenAlexW4390630344

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.